Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma

NCT05633615 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT05633615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05633615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Recruiting
Start date
June 12, 2023
Completion date
June 30, 2030
Enrollment
396 (estimated)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, grade 3b follicular lymphoma, primary mediastinal (thymic) large b-cell lymphoma, recurrent diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, transformed follic lymph to diff large b-cell lymphoma, transformed marg zone lymph to diff large b-cell lymphoma